US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Femasys Inc. - Common Stock (NQ:FEMY)

2.020 -0.030 (-1.46%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
From Femasys Inc.
Via GlobeNewswire
News headline image
Top stock movements in today's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Crude Oil Down 2%; US Durable Goods Orders Decline In July ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
US Stocks Mixed; American Woodmark Posts Downbeat Sales ↗
 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Revenue Jumps 85 Percent in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Femasys Announces Second Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women-- 
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Femasys In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up ↗
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday. 
Via Stocktwits
News headline image
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >